Avalo Therapeutics
AVTX
AVTX
70 hedge funds and large institutions have $136M invested in Avalo Therapeutics in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
1% less funds holding
Funds holding: 71 → 70 (-1)
22% less capital invested
Capital invested by funds: $176M → $136M (-$39.5M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
70
Holding in Top 10
–
Calls
$143K
Puts
$100K
Top Buyers
| 1 | +$1.31M | |
| 2 | +$1.12M | |
| 3 | +$328K | |
| 4 |
D.E. Shaw & Co
New York
|
+$275K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$147K |
Top Sellers
| 1 | -$1.17M | |
| 2 | -$737K | |
| 3 | -$720K | |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$589K |
| 5 |
Two Sigma Advisers
New York
|
-$552K |